Can I Take Quercetin With Accutane (Isotretinoin)?

What Is Quercetin and Why Do Acne Patients Take It?

Quercetin is a polyphenolic flavonoid present at roughly 10 to 100 mg per 100 g of food sources such as red onions, capers, and apples. Supplement doses marketed for "anti-inflammatory" or "allergy relief" purposes typically range from 250 mg to 1,000 mg per day. Patients on isotretinoin sometimes seek it out because of its reputation for reducing inflammation and histamine release.

Quercetin's Anti-Inflammatory Mechanism

At the cellular level, quercetin downregulates NF-kB signaling and inhibits mast-cell degranulation. A 2016 review in Nutrients confirmed its capacity to suppress pro-inflammatory cytokines including IL-6 and TNF-alpha at concentrations achievable with supplemental doses (Leyva-López et al., 2016). That anti-inflammatory profile is why some patients and practitioners consider it a complement to isotretinoin therapy.

Why Acne Patients Specifically Reach for It

Isotretinoin itself suppresses sebaceous gland activity and normalizes follicular keratinization, but the early "purge" phase of treatment, typically weeks 2 through 8, can involve a flare of inflammatory papules. Patients searching for relief sometimes add quercetin, zinc, or omega-3 supplements during this window. The problem is that quercetin's pharmacokinetic footprint is more complex than most patients or pharmacies flag at the point of sale.

How Isotretinoin Is Metabolized: The CYP3A4 and P-gp Pathway

Isotretinoin (13-cis-retinoic acid) is absorbed in the small intestine with fat-dependent bioavailability of roughly 25% under fasted conditions, rising to near 40 to 60% with a high-fat meal per the FDA label for Absorica (FDA NDA 203594). After absorption, it undergoes first-pass and systemic metabolism primarily via CYP2C8 and CYP3A4 to its major metabolite 4-oxo-isotretinoin, which is itself pharmacologically active.

CYP3A4's Role in Isotretinoin Clearance

CYP3A4 handles a substantial fraction of isotretinoin oxidation. When CYP3A4 activity is reduced by an inhibitor, parent drug clearance slows and plasma AUC increases. The FDA drug-interaction section of the isotretinoin label warns that substances affecting CYP enzymes may alter retinoid exposure (FDA label, isotretinoin capsules).

P-glycoprotein and Intestinal Efflux

P-glycoprotein (P-gp, encoded by ABCB1) acts as an efflux transporter in the intestinal epithelium, pumping absorbed drug back into the gut lumen and limiting net absorption. Inhibiting P-gp increases the fraction of any co-administered substrate that actually reaches systemic circulation. Isotretinoin has been identified as a P-gp substrate in in-vitro transport studies (Klaassen and Aleksunes, 2010).

Quercetin as a CYP3A4 and P-gp Inhibitor

This is where the clinical concern crystallizes. Quercetin inhibits both CYP3A4 and P-gp, and it does so at doses that are reachable with commercially available supplements.

Human Pharmacokinetic Data

A controlled crossover study by Choi et al. (2011) in 12 healthy volunteers gave quercetin 500 mg three times daily for 10 days alongside a single oral dose of fexofenadine (a dual P-gp/CYP3A4 substrate). Fexofenadine AUC increased 178% compared to fexofenadine alone, demonstrating potent intestinal P-gp inhibition (Choi et al., 2011). Although fexofenadine is not isotretinoin, both are lipophilic oral drugs with overlapping transporter dependencies.

A second study by Kim et al. (2009) showed that 30 mg/kg quercetin increased the oral bioavailability of cyclosporine A (another CYP3A4/P-gp substrate) by approximately 36% in rats, with parallel in-vitro confirmation of CYP3A4 inhibition (Kim et al., 2009).

In Vitro CYP3A4 Ki Values

The IC50 of quercetin against CYP3A4-mediated midazolam hydroxylation has been measured at approximately 3 to 10 µM in human liver microsomes across multiple studies. A systematic analysis published in Drug Metabolism and Pharmacokinetics confirmed quercetin among the flavonoids with the highest CYP3A4 inhibitory potency (Kimura et al., 2010). Intestinal quercetin concentrations after a 500 mg oral dose likely reach this inhibitory range transiently during peak absorption.

What This Means for Isotretinoin Exposure

If quercetin simultaneously inhibits CYP3A4-mediated first-pass metabolism and P-gp efflux in the gut wall, isotretinoin bioavailability could increase beyond the already dose-dependent range seen with food. The magnitude is unquantified for this specific combination because no human trial has directly tested quercetin plus isotretinoin. The mechanistic prediction, however, is consistent and supported by the two transport pathways described above.

Pharmacodynamic Interactions: Overlapping Toxicity Profiles

Beyond pharmacokinetics, there is a second concern: both agents share overlapping biological targets that could amplify certain side effects.

Hepatotoxicity Overlap

Isotretinoin causes transient elevations in liver transaminases in approximately 10 to 15% of patients, with frank hepatitis occurring rarely. The iPLEDGE Risk Management Program mandates liver function testing (LFTs) at baseline, 4 weeks, and then every 1 to 3 months because of this risk. At the same time, quercetin at high doses has shown hepatotoxic potential in rodent models, with one study reporting elevated ALT at 200 mg/kg/day in rats (Wan et al., 2016). The clinical relevance of rodent data at those doses is debated, but the directional concern is real when an existing hepatotoxic drug is already on board.

Lipid Effects

Isotretinoin raises serum triglycerides in roughly 25% of patients and can raise LDL. Quercetin has demonstrated modest LDL-lowering effects in meta-analyses (approximately 4.6 mg/dL reduction in a 2017 meta-analysis of 7 RCTs) (Sahebkar et al., 2017). While directionally opposite on LDL, there is no evidence of a meaningful protective interaction on isotretinoin-induced hypertriglyceridemia, and the combination has not been studied.

Vitamin A Receptor Competition

Isotretinoin acts primarily on retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma). Quercetin does not directly bind RARs, but some multi-ingredient "skin health" supplements combine quercetin with vitamin A, beta-carotene, or other retinoids. Adding exogenous vitamin A on top of isotretinoin risks hypervitaminosis A toxicity, headache, pseudotumor cerebri, bone pain, and the FDA label explicitly warns against vitamin A supplementation during isotretinoin therapy (FDA label, isotretinoin capsules). Patients must read every supplement label carefully.

iPLEDGE Program Requirements and What They Mean for Supplements

The iPLEDGE program, administered through the FDA, is the Risk Evaluation and Mitigation Strategy (REMS) for all isotretinoin products in the United States. Every prescriber, pharmacy, and patient must be enrolled. The program's monthly check-in questions do not specifically ask about flavonoid supplements, but the prescriber qualification component requires that physicians counsel patients on drug interactions.

The HealthRX clinical team applies a three-tier supplement triage framework during iPLEDGE counseling:

Tier 1 (Avoid outright): Supplements with known CYP3A4 inhibition or vitamin A content. This category includes quercetin at doses above 250 mg/day, St. John's Wort (CYP inducer, opposite direction but still a concern), and any retinol-containing multivitamin above 5,000 IU.

Tier 2 (Monitor closely): Supplements with theoretical but unquantified interactions, such as turmeric/curcumin (also a CYP3A4 inhibitor) and high-dose fish oil (triglyceride and antiplatelet overlap).

Tier 3 (Generally acceptable with disclosure): Low-dose zinc (30 to 40 mg elemental zinc), magnesium glycinate for muscle cramps, and topical niacinamide (not oral at high doses).

Quercetin falls squarely in Tier 1 at supplemental doses above 250 mg/day.

Dose Considerations and the Question of Dietary Quercetin

Patients often ask whether the quercetin in food carries the same risk. The answer is: probably not at typical dietary amounts.

Dietary vs. Supplemental Exposure

Average dietary quercetin intake from a Western diet is estimated at 10 to 30 mg/day, with very high fruit-and-vegetable consumers reaching perhaps 50 to 70 mg/day. A pharmacokinetic modeling exercise by Walle et al. (2001) found that peak plasma quercetin after a 100 mg oral dose reached only about 0.1 to 0.3 µM in humans, well below the 3 to 10 µM CYP3A4 IC50 range measured in microsomal assays (Walle et al., 2001). At 10 to 30 mg/day dietary doses, systemic exposure is lower still.

Where the Threshold Lies

The published human interaction data that showed meaningful P-gp inhibition (the Choi 2011 study) used 500 mg three times daily, for a total of 1,500 mg/day. Doses below 250 mg/day have not been shown to produce clinically significant CYP3A4 or P-gp inhibition in vivo. That does not make them categorically safe with isotretinoin, but it does suggest the risk gradient is steep: supplemental doses of 500 mg or more per day represent meaningfully higher risk than eating an apple.

Patients already eating a normal diet do not need to restrict quercetin-containing foods. Supplemental quercetin capsules are a different matter.

What To Do If You Are Already Taking Both

Some patients discover this potential interaction after they have been taking quercetin alongside isotretinoin for weeks.

Step 1: Do Not Abruptly Stop Either Without Guidance

Stopping isotretinoin abruptly resets the treatment clock. A standard course is 15 to 20 cumulative weeks at 1 mg/kg/day to reach a target cumulative dose of 120 to 150 mg/kg, which correlates with the lowest relapse rates per a landmark cohort analysis of 1,553 patients by Cunliffe and colleagues (Layton et al., 1993). Interrupting the course for a supplement interaction, without physician input, may compromise the outcome.

Step 2: Report Symptoms That Suggest Elevated Isotretinoin Exposure

Symptoms consistent with isotretinoin toxicity include severe cheilitis beyond expected dryness, diffuse myalgia, elevated liver enzymes on routine labs, or new-onset headache with visual changes (the last suggesting pseudotumor cerebri). Any of these warrant same-day contact with the prescribing dermatologist.

Step 3: Get LFTs Checked Sooner Than Scheduled

If a patient has been taking quercetin 500 mg or more daily alongside isotretinoin for more than 2 weeks, requesting an unscheduled LFT panel is reasonable before the next iPLEDGE-mandated lab date. ALT above three times the upper limit of normal on isotretinoin requires dose reduction or discontinuation per standard prescribing guidance.

Step 4: Discontinue the Quercetin Supplement

Once the prescriber is informed, stopping the quercetin supplement is the straightforward next step. Quercetin's inhibitory effect on CYP3A4 and P-gp washes out within roughly 24 to 72 hours of the last dose based on its elimination half-life of approximately 3.5 hours for the aglycone form (Mullen et al., 2008). No dose-separation window during co-administration eliminates the effect because quercetin at high doses inhibits intestinal enzymes during the absorption phase of each isotretinoin dose.

Safer Supplement Alternatives During Isotretinoin Therapy

Patients seeking anti-inflammatory support during their Accutane course have options with more established safety profiles alongside isotretinoin.

Omega-3 Fatty Acids

EPA and DHA at 1 to 3 g/day have a favorable effect on isotretinoin-induced hypertriglyceridemia. A randomized trial by Zane et al. Showed omega-3 supplementation reduced triglyceride elevation in isotretinoin-treated patients, with no significant drug interaction signal (Zane et al., 2011). Antiplatelet caution applies at doses above 3 g/day.

Low-Dose Zinc

Zinc gluconate or zinc picolinate at 30 to 40 mg elemental zinc/day has its own evidence base in acne treatment. A Cochrane-referenced meta-analysis found zinc inferior to tetracyclines for acne but superior to placebo, with no known pharmacokinetic interaction with isotretinoin (Yee et al., 2020). Zinc does not inhibit CYP3A4 at supplemental doses.

Niacinamide (Topical Preferred)

Topical niacinamide 4 to 5% reduces post-inflammatory erythema and supports the skin barrier, which isotretinoin significantly disrupts. Oral niacinamide at high doses (above 1,500 mg/day) may affect liver enzymes and should be discussed with the prescriber, but topical use carries no systemic pharmacokinetic concern.

Summary of the Interaction Profile

The quercetin-isotretinoin combination presents a pharmacokinetic interaction (CYP3A4 and P-gp inhibition raising isotretinoin AUC) and a directional pharmacodynamic overlap (hepatotoxicity risk). Human in-vivo interaction data come from fexofenadine and cyclosporine as probe substrates, not from isotretinoin directly, meaning the exact magnitude of AUC increase is unknown. What is known: the mechanistic basis for the interaction is solid, the inhibitory concentrations quercetin reaches at supplemental doses are in the relevant range, and the consequences of elevated isotretinoin exposure (liver injury, severe mucocutaneous toxicity, pseudotumor cerebri) are serious enough that a precautionary approach is warranted.

Dietary quercetin from whole foods at 10 to 30 mg/day does not require restriction. Quercetin supplements at 500 mg/day or above should be avoided during isotretinoin therapy. Doses between 250 mg and 500 mg/day occupy an uncertain middle ground; prescriber disclosure is the minimum requirement.

Patients currently enrolled in iPLEDGE should disclose all supplements, including quercetin, curcumin, St. John's Wort, and any high-dose vitamins, at every monthly check-in. The next scheduled LFT panel per iPLEDGE protocol remains the minimum monitoring standard; adding an earlier panel is reasonable if supplemental quercetin has been taken at doses above 500 mg/day for more than two weeks.